High-throughput SARS-CoV-2 Total Antibody Immunoassay

Long-term monitoring and pandemic management of COVID-19

SARS-CoV-2 Total Antibody Immunoassay - launch Q4 2021

In the effort to contain the COVID-19 pandemic serological testing to detect SARS-CoV-2 specific antibodies will be important in disease and community management.

Gentian is developing a turbidimetric SARS-CoV-2 Total Antibody Immunoassay in collaboration with the University in Tromsø (UiT).  The quantitative antibody test captures the full immune response detecting antibodies targeting the S1 subunit with high sensitivity and specificity and will be calibrated against the international WHO standard.

sars-cov2_ab-test_-web-ready

Increased testing capacity

Gentian will bring SARS-CoV-2 serology testing to automated, open-access clinical chemistry platforms, increasing both the testing capacity (up to 2000 tests/hour) and the laboratory efficiency. Since the Gentian assay is platform agnostic it can be seamlessly integrated in daily laboratory routine without additional infrastructure or workflow cost. The test will follow a standard testing protocol utilising existing logistic structure, from the routine blood test at the GP office to the clinical chemistry platforms with an assay time of only 10 minutes.

Following the antibody levels and immune status of the society

The Gentian assay will provide the tool to achieve documented protection for individuals and society. It allows the tracking of the total antibody response targeting the S1 subunit, to assess the level of protection. It will provide a powerful high-throughput test for community management of COVID-19 through long-term monitoring of natural and vaccine-related immune response. 

shot---covid-antibody.square-web-ready
sars-cov2_ab-test-who-web-ready

Standardised against the First WHO International Standard

The Gentian SARS-CoV-2 Total Antibody Immunoassay is calibrated against the WHO International Standard for anti-SARS-CoV-2 antibody, enabling harmonisation between results across laboratories and serological assays. The standardisation allows scientist, health care workers and laboratories to directly compare results, minimising variation and calibration correction.

1-2

Turbidimetric test

17

Faster throughput

2-3

Open channel

Total antibody

Capture Total Ab Response

Target S1-subunit

Target S1-subunit

First WHO International Standard

First WHO International Standard

Contact us for more information 

Let us know if you want more information about the assay or want to validate the assay in your laboratory at the time of launch.

Please send us an email to marketing@gentian.com or fill out the form to the right. Our Product Manager for SARS-CoV-2 Total Antibody Immunoassay will get in touch.

FAQ - Gentian SARS-CoV-2 Total Antibody Immunoassay?

Which antigen is the target of Gentian SARS-CoV-2 Total Antibody Immunoassay?
The Gentian SARS-CoV-2 Total Antibody Immunoassay will capture the antibody response to the S1-antigen of the SARS-CoV-2.
Will the Gentian SARS-CoV-2 Total Antibody Immunoassay capture the total antibody response?
The Gentian SARS-CoV-2 Total Antibody Immunoassay will capture the IgG, IgM and IgA antibody response.
How is the calibrator standardised?
The Gentian SARS-CoV-2 Total Antibody Immunoassay is standardised to the First WHO International Standard Anti-SARS-CoV-2 Immunoglobulin WHO/BS/2020.2402.
Is the Gentian SARS-CoV-2 Total Antibody Immunoassay available on all clinical chemistry analysers?
The Gentian SARS-CoV-2 Total Antibody Immunoassay is an open channel assay and applicable to most major clinical analyser. Please contact marketing@gentian.com for more information on availability on the clinical analyser in your laboratory.